Castle Biosciences Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
1,048
- Stock Symbol
-
CSTL
- Investments
-
5
- Share Price
-
$32.91
- (As of Friday Closing)
Castle Biosciences General Information
Description
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Contact Information
Website
www.castlebiosciences.comCorporate Office
- 1500 West Parkwood Avenue
- Suite 400
- Friendswood, TX 77546
- United States
Corporate Office
- 1500 West Parkwood Avenue
- Suite 400
- Friendswood, TX 77546
- United States
Castle Biosciences Stock Performance
As of 20-Nov-2026, Castle Biosciences’s stock price is $32.91. Its current market cap is $1.01B with 30.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $32.91 | $33.41 | $17.72 - $44.28 | $1.01B | 30.8M | 385K | -$0.77 |
Castle Biosciences Financials Summary
As of 30-Sep-2026, Castle Biosciences has a trailing 12-month revenue of $377M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 855,269 | 885,036 | 493,350 | 365,503 |
| Revenue | 377,126 | 344,229 | 332,069 | 219,788 |
| EBITDA | (16,425) | (429) | 25,222 | (55,647) |
| Net Income | (23,014) | (24,158) | 18,245 | (57,466) |
| Total Assets | 579,408 | 578,556 | 531,235 | 453,340 |
| Total Debt | 36,574 | 36,913 | 26,344 | 15,335 |
Castle Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Castle Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Castle Biosciences Comparisons
Industry
Financing
Details
Castle Biosciences Competitors (28)
One of Castle Biosciences’s 28 competitors is Myriad Genetics, a Corporation company based in Salt Lake City, UT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| Veracyte | Formerly VC-backed | South San Francisco, CA | ||||
| Biocept | Formerly VC-backed | San Diego, CA | ||||
| Decipher Urologic Cancers | Formerly VC-backed | San Diego, CA | ||||
| Cardiff Oncology | Formerly Angel backed | San Diego, CA |
Castle Biosciences Patents
Castle Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183498-A1 | Diagnosing and treatment uveal melanoma | Pending | 28-Feb-2025 | ||
| WO-2026036140-A1 | Method and kit for isolating and sequencing nucleic acid from skin samples | Pending | 09-Aug-2024 | ||
| EP-4676593-A1 | Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides | Pending | 10-Mar-2023 | ||
| WO-2024191957-A1 | Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides | Inactive | 10-Mar-2023 | ||
| US-20220285032-A1 | Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores | Inactive | 08-Mar-2021 | G16H50/30 |
Castle Biosciences Signals
Castle Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Castle Biosciences Investments & Acquisitions (5)
Castle Biosciences’s most recent deal was a PIPE with SciBase for . The deal was made on 17-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SciBase | 17-Jun-2025 | PIPE | Diagnostic Equipment | ||
| Previse (Biotechnology) | 01-May-2025 | Merger/Acquisition | Diagnostic Equipment | ||
| AltheaDx | 26-Apr-2022 | Merger/Acquisition | Practice Management (Healthcare) | ||
| Cernostics | 03-Dec-2021 | Merger/Acquisition | Decision/Risk Analysis | ||
| Myriad myPath Melanoma | 28-May-2021 | Merger/Acquisition | Diagnostic Equipment |
Castle Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
21.9 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Services
Subindustry
of 97
Rank
Percentile
Castle Biosciences FAQs
-
When was Castle Biosciences founded?
Castle Biosciences was founded in 2008.
-
Where is Castle Biosciences headquartered?
Castle Biosciences is headquartered in Friendswood, TX.
-
What is the size of Castle Biosciences?
Castle Biosciences has 1,048 total employees.
-
What industry is Castle Biosciences in?
Castle Biosciences’s primary industry is Laboratory Services (Healthcare).
-
Is Castle Biosciences a private or public company?
Castle Biosciences is a Public company.
-
What is Castle Biosciences’s stock symbol?
The ticker symbol for Castle Biosciences is CSTL.
-
What is the current stock price of Castle Biosciences?
As of 20-Nov-2026 the stock price of Castle Biosciences is $32.91.
-
What is the current market cap of Castle Biosciences?
The current market capitalization of Castle Biosciences is $1.01B.
-
What is Castle Biosciences’s current revenue?
The trailing twelve month revenue for Castle Biosciences is $377M.
-
Who are Castle Biosciences’s competitors?
Myriad Genetics, Veracyte, Biocept, Decipher Urologic Cancers, and Cardiff Oncology are some of the 28 competitors of Castle Biosciences.
-
What is Castle Biosciences’s annual earnings per share (EPS)?
Castle Biosciences’s EPS for 12 months was -$0.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process